Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry-Reference-Cited by-同舟云学术

Prevalence of cardiovascular diseases and traditional cardiovascular risk factors in patients with rheumatoid arthritis: a real-life evidence from BioSTAR nationwide registry

Published:2023-12-29 Issue:2 Volume:44 Page:291-301
ISSN:1437-160X
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Duruöz Mehmet Tuncay^ORCID,Ataman Şebnem^ORCID,Bodur Hatice^ORCID,Çay Hasan Fatih^ORCID,Melikoğlu Meltem Alkan^ORCID,Akgül Özgür^ORCID,Çapkın Erhan^ORCID,Gürer Gülcan^ORCID,Çevik Remzi^ORCID,Göğüş Feride Nur^ORCID,Kamanlı Ayhan^ORCID,Yurdakul Fatma Gül^ORCID,Yağcı İlker^ORCID,Rezvani Aylin^ORCID,Altan Lale^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s00296-023-05515-y.pdf

Reference47 articles.

1. Raj R, Thomas S, Gorantla V (2022) Accelerated atherosclerosis in rheumatoid arthritis: a systematic review. F1000Res 11:466. https://doi.org/10.12688/f1000research.112921.1

2. Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z (2022) Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-222259

3. Yu KH, Chen HH, Cheng TT, Jan YJ, Weng MY, Lin YJ, Chen HA, Cheng JT, Huang KY, Li KJ, Su YJ, Leong PY, Tsai WC, Lan JL, Chen DY (2022) Consensus recommendations on managing the selected comorbidities including cardiovascular disease, osteoporosis, and interstitial lung disease in rheumatoid arthritis. Medicine (Baltimore) 101(1):e28501. https://doi.org/10.1097/MD.0000000000028501

4. Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J (2022) ARTIS study group. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. https://doi.org/10.1136/ard-2022-223050

5. Aronov A, Kim YJ, Sweiss NJ, Nazir NT (2022) Cardiovascular disease risk evaluation impact in patients with rheumatoid arthritis. Am J Prev Cardiol 14(12):100380. https://doi.org/10.1016/j.ajpc.2022.100380